Tolerance to Hemodialysis in Insulin-Requiring Diabetic Patients: BD vs AFB With Blood Volume Biofeedback (THIRD)

This study has been completed.
Sponsor:
Information provided by:
Università degli Studi di Brescia
ClinicalTrials.gov Identifier:
NCT01098149
First received: March 29, 2010
Last updated: April 1, 2010
Last verified: March 2010
  Purpose

Diabetic nephropathy is becoming the most common primary renal disease in end stage renal disease patients. The prevalence of diabetic patients in dialysis reaches even the 30% of the dialysis population (USRDS) with an incidence rate, in some countries, up to 40%. The 5 years surviving time of diabetic patients in dialysis is about the 20% and, compared to the hypertension and glomerulonephritis complications, still remains the worst. Diabetes is often associated to several comorbid factors such as hypertension, autonomic neuropathy, vasculopathy, metabolic disorders (ketoacidosis, poor glycaemic control), and electrolyte disorders. So, the diabetic patient is fragile, with a rather poor tolerance to dialysis, lack of achievement of dry body weight and inadequate dialysis. In order to gain a more detailed insight into a possible better tolerance to dialysis, arising from the elimination of acetate in dialysate bath (Acetate Free Biofiltration) and from the use of an automatic system to control the blood volume (Blood Volume Control),the investigators would like to investigate the cardiovascular stability and the frequency of intradialytic symptoms in a prospective, randomized, cross-over study.


Condition Intervention
Hypotension
Hemodialysis
Other: BD and BVC, AFB

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Tolerance to Hemodialysis in Insulin-Requiring Diabetic Patients: a Prospective Randomized,Cross-over Multicenter Study Between Bicarbonate Dialysis (BD) and Blood Volume Controlled Acetate-Free Biofiltration (BVC-AFB)

Resource links provided by NLM:


Further study details as provided by Università degli Studi di Brescia:

Primary Outcome Measures:
  • Investigate a possible better tolerance to dialysis, eliminating acetate in the dialysate bath, with AFB treatment, and using, at the same time, the automatic blood volume control (BVC). [ Time Frame: 3 months ] [ Designated as safety issue: No ]

    The treatment tolerance is measured by the number of intradialytic hypotensive events, defined as:

    • systolic blood pressure less then 90 mmHg;
    • systolic blood pressure more then 25 mmHg to the predialysis value, with hypotensive events requiring therapies;
    • systolic blood pressure less then 90 mmHg with hypotensive events requiring therapies for those patients, which predialysis systolic blood pressure value was 100 mmHg.


Secondary Outcome Measures:
  • The secondary outcome measure is to evaluate the relative efficiency of each factor (AFB in the bath and blood volume control) to reach this result. [ Time Frame: 3 months ] [ Designated as safety issue: No ]

    The evaluation will be done on:

    • frequency of hypotensive events, during dialysis (defined as above);
    • number of nurse interventions (defined as ultrafiltration rate stop, or saline infusion);
    • antihypertensive drugs.


Enrollment: 55
Study Start Date: March 2006
Study Completion Date: March 2010
Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: AFB stand alone
Patients are switched in AFB treatment, without blood volume control.
Other: BD and BVC, AFB
Some patients are randomized into the AFB, the others into the BD and BVC
Other Name: Biofeedback,Blood Volume Control,Acetate Free Biofiltration
Active Comparator: BD and BVC
Patients are switched into bicarbonate dialysis with Blood Volume Control
Other: BD and BVC, AFB
Some patients are randomized into the AFB, the others into the BD and BVC
Other Name: Biofeedback,Blood Volume Control,Acetate Free Biofiltration

Detailed Description:

Acetate-Free-Biofiltration (AFB) was proved to be a technique suitable to treat critical patients, such as elders and diabetics, because of frequency reduction of hypotensive episodes and symptoms during the treatment and a better control to metabolic aspects (such as metabolic acidosis).

The Blood Volume Control (BVC) is a tool, that allows to improve the cardiovascular tolerance to the treatment, especially in hypotension-prone patients, appearing promising in the correction of the arterial hypertension induced by the hydro-saline overload.

The use of BVC in AFB has been tested to verify the behaviour of the kinetics of electrolyte (in particular of bicarbonate) and it has got good results, in terms of a further improvement in treatment tolerance, for critical patients However, this therapy (AFB+BVC) was not yet evaluated as the dialysis tolerance improvement in diabetics concern, nor the relative contribution given by each factor in achieving this result.

The study, 9 months long, is aimed to verify the treatment tolerance of insulin requiring diabetic patients, by using standard bicarbonate dialysis (BD), or Acetate Free Biofiltration (AFB) and/or a Blood Volume Control(BVC). The study is divided in three phases: the first one, three months long, is the baseline in standard bicarbonate dialysis, then all the patients are shifted to AFB with BVC, for other three months, while the last three months long phase, after a randomization, has the aim to identify the relative contribution of each factor (absence of acetate in the bath or BVC) in the treatment tolerance improvement(if any). The treatment tolerance will be evaluated considering the frequency of intradialytic hypotensive events.

  Eligibility

Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • End stage renal disease patients
  • Patients affected by diabetic nephropathy with insulin therapy, for, at least, 6 months
  • Patients with renal replacement therapy with haemodialysis three time a week, for, at least, 6 months.
  • Age between 18 and 85 years

Exclusion Criteria:

  • Patients affected by neoplasm and/or mental illness
  • Patients with residual diuresis > 500 ml/die;
  • Patients in single needle bicarbonate dialysis.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01098149

Locations
Italy
Hospital "Santa Maria della Scaletta"
Imola, Bologna, Italy
Hospital "Nuovo Ronco"
Gussago, Brescia, Italy
Hospital "Policlinico S.Orsola-Malpighi"
Bologna, Italy
Hospital "Spedali Civili"
Brescia, Italy
Hospital "Degli Infermi"
Rimini, Italy
Sponsors and Collaborators
Università degli Studi di Brescia
Investigators
Study Chair: Giovanni Cancarini, MD Università of Brescia
  More Information

Publications:
Responsible Party: Dott.Ezio Movilli, Dept of Nephrology -Brescia
ClinicalTrials.gov Identifier: NCT01098149     History of Changes
Other Study ID Numbers: THIRD-01
Study First Received: March 29, 2010
Last Updated: April 1, 2010
Health Authority: Italy: Ethics Committee

Keywords provided by Università degli Studi di Brescia:
Haemodialysis treatment tolerance
acetate free biofiltration
frequency of hypotensive events during dialysis
nurse intervention during dialysis

Additional relevant MeSH terms:
Hypotension
Vascular Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on July 28, 2014